Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Recruiting 13Completed 11Active not recruiting 10Withdrawn 5Unknown 4Terminated 2Suspended 1Not yet recruiting 1No longer available 1Available 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4Sarcoma 2Other hematologic neoplasm 2Lymphoid 2Thoracic 1Gastrointestinal 1

Conditions

Multiple Myeloma 4

Interventions

Dexamethasone 70Cyclophosphamide 44Bortezomib 41Lenalidomide 25Melphalan 24Thalidomide 19pomalidomide 17daratumumab 14fludarabine 13carfilzomib 10Filgrastim 8Doxorubicin 8Busulfan 6isatuximab 5Prednisone 5Peripheral Blood Stem Cell Transplantation 5Calcium Dobesilate 5Bendamustine Hydrochloride 5selinexor 4sargramostim 4fludarabine phosphate 4Surveys and Questionnaires 4Etoposide 4Clarithromycin 4liposomal doxorubicin 3ixazomib 3dexamethasone acetate 3Radiotherapy 3Neoadjuvant Therapy 3Mycophenolic Acid 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Unknown × selinexor × Plasma cell × Clear all
NCT04877275 2023-12-06

ATG-010(Selinexor) in Combination With Chemotherapy in RRMM

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Unknown
50 enrolled
Plasma cell

Multiple Myeloma

NCT04519476 2023-10-31

Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.

Oncotherapeutics

Phase 1 Unknown
22 enrolled
Plasma cell

Multiple Myeloma

NCT04941937 2023-02-27

Selinexor in Combination With Immunomodulator (Thalidomide/Pomalidomide/Lenalidomide)in RRMM

Shanghai Changzheng Hospital

Phase 2 Unknown
90 enrolled
Plasma cell

Multiple Myeloma

NCT04891744 2021-05-18

Selinexor in Combination With Thalidomide and Dexamethasone in RRMM

Sichuan University

Phase 1/2 Unknown
48 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚔